Advanced search
Publication Cover
Cancer Biology & Therapy Volume 16, 2015 - Issue 11
Submit an article Journal homepage
1,501
Views
14
CrossRef citations to date
0
Altmetric
Clinical Study

Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study

Feng WenDepartment of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Chengdu, China;West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China; These authors contributed equally to this work.
,
Yu YangDepartment of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Chengdu, China;West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China; These authors contributed equally to this work.
,
Pengfei ZhangDepartment of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Chengdu, China;West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China
,
Jian ZhangDepartment of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Chengdu, China;West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China
,
Jing ZhouDepartment of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Chengdu, China;West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China
,
Ruilei TangDepartment of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Chengdu, China;West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China
,
Hongdou ChenDepartment of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Chengdu, China;West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China
,
Hanrui ZhengWest China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China;Department of Clinical Pharmacy; West China Hospital; Sichuan University; Chengdu, China
,
Ping FuWest China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, China;Division of Nephrology of Department of Internal Medicine; West China Hospital; Sichuan University; Chengdu, China
&
Qiu LiDepartment of Medical Oncology; Cancer Center; State Key Laboratory of Biotherapy; West China Hospital; Sichuan University; Chengdu, China;West China Biostatistics and Cost-Benefit Analysis Center; Sichuan University; Chengdu, ChinaCorrespondence[email protected]
 show all
Pages 1577-1584 | Received 01 Apr 2015, Accepted 12 Sep 2015, Published online: 04 Nov 2015

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Liangliang Bai, Pengfei Zhang, Kexun Zhou, Weiting Liao & Qiu Li. (2019) Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer. Cancer Management and Research 11, pages 10419-10426.
Read now

Articles from other publishers (13)

Laura A. Barufaldi, Rita de C.R. de Albuquerque, Aline do Nascimento, Luís Felipe L. Martins, Ivan R. Zimmermann & Mirian C. de Souza. (2023) Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer. Value in Health Regional Issues 37, pages 33-40.
Crossref
Liu Liu, Zhixin Jiang, Fuming Li, Yan Wei, Jian Ming, Yi Yang, Shimeng Liu, Lizheng Shi & Yingyao Chen. (2022) Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list. BMC Health Services Research 22:1.
Crossref
Mikyung Kelly Seo & John Cairns. (2021) How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review. BMC Cancer 21:1.
Crossref
Stavroula Koilakou & Panagiotis Petrou. (2021) Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. Molecular Diagnosis & Therapy 25:6, pages 715-734.
Crossref
Koen Degeling, Martin Vu, Hendrik Koffijberg, Hui-Li Wong, Miriam Koopman, Peter Gibbs & Maarten IJzerman. (2020) Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. PharmacoEconomics 38:7, pages 683-713.
Crossref
Jiaqi Han, Desheng Xiao, Chongqing Tan, Xiaohui Zeng, Huabin Hu, Shan Zeng, Qin Jiang, Longjiang She, Linli Yao, Li Li, Lanhua Tang, Jian Ma, Jin Huang & Liangfang Shen. (2020) Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Cancer Control 27:1, pages 107327482090227.
Crossref
Feng Wen, Hanrui Zheng, Pengfei Zhang, Jing Zhou, Hongdou Chen, Kexun Zhou, Qiu Li & Feng Bi. (2019) Patient‐based cost‐effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4‐year prospective randomised phase II study. European Journal of Cancer Care 29:1.
Crossref
Shichao Wang, Feng Wen, Pengfei Zhang, Xin Wang & Qiu Li. (2019) Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer. Radiation Oncology 14:1.
Crossref
Fahim FaruqueHeejung NohArif HussainEdward NeubergerEberechukwu Onukwugha. (2019) Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review. Journal of Managed Care & Specialty Pharmacy 25:2, pages 260-271.
Crossref
Mikyung Kelly Seo & John Cairns. (2018) Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLOS ONE 13:9, pages e0204496.
Crossref
Gerard Harty, James Jarrett & Mireia Jofre-Bonet. (2018) Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work. Applied Health Economics and Health Policy 16:4, pages 515-525.
Crossref
Shota Saito, Hitoshi Kameyama, Yusuke Muneoka, Shujiro Okuda, Toshifumi Wakai & Kouhei Akazawa. (2017) Cost-effectiveness analysis of the use of comprehensive molecular profiling before initiating monoclonal antibody therapy against metastatic colorectal cancer in Japan. Journal of Cancer Policy 12, pages 61-66.
Crossref
Giorgio Stanta, Stephan Wenzel Jahn, Serena Bonin & Gerald Hoefler. (2016) Tumour heterogeneity: principles and practical consequences. Virchows Archiv 469:4, pages 371-384.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.